Business Context and Reporting Period
This Form 8-K, filed on July 13, 2015, by Platform Specialty Products Corporation ("Platform"), discloses the entry into a material definitive agreement to acquire Alent plc ("Alent"). The transaction is structured as a recommended offer via a court-sanctioned scheme of arrangement under U.K. law. Platform intends to acquire all issued and to-be-issued shares of Alent, a public limited company registered in England and Wales.
Key Financial Metrics and Transaction Terms
- Transaction Value: The acquisition values Alent's entire share capital at approximately £1,351 million ($2,096 million based on a GBP/USD exchange rate of 1.5517).
- Consideration: Alent shareholders are entitled to receive 503 pence in cash per share. Alternatively, eligible shareholders may elect to receive Platform common stock at a ratio of 0.31523 New Platform Shares for every Alent Share.
- Share Alternative Cap: The share alternative is limited to approximately 21.9% of Alent's issued share capital as of July 10, 2015. Excess elections will be scaled down pro rata.
- Financing: Platform secured an interim senior unsecured term loan facility of $1.875 billion from Credit Suisse AG and affiliates. If not repaid within 30 days, this converts to a 366-day bridge facility with an initial interest rate of up to 8.75% per annum.
- Break Fee: Platform agreed to pay Alent a break fee of £27 million if the acquisition lapses due to unsatisfied regulatory conditions or if Platform invokes a regulatory condition to terminate the deal.
Material Changes and Conditions
The filing represents a material change in Platform's corporate structure and capital obligations. The acquisition is subject to several conditions, including:
- Approval by requisite majorities of Alent shareholders and sanction by the High Court of England and Wales.
- Expiration of the Hart-Scott-Rodino waiting period and receipt of other necessary antitrust clearances.
- Absence of a material adverse change in Alent's business, assets, or financial position.
- Irrevocable Undertaking: Cevian Capital II Master Fund LP, Alent's largest shareholder, has agreed to vote in favor of the scheme and elect the partial share alternative for its entire holding of 58,432,694 shares.
Guidance, Outlook, and Risks
Timeline: Completion is expected in late 2015 or early 2016, subject to conditions. The "Long Stop Date" for regulatory conditions is July 13, 2016.
Management Commentary: Platform disclosed a "Quantified Financial Benefits Statement" regarding estimated cost savings and synergies, verified by PricewaterhouseCoopers LLP and Credit Suisse Securities (Europe) Limited. The filing notes that the interim financing is expected to be replaced with permanent financing before or after closing.
Risks and Contingencies:
- Regulatory Risk: Failure to obtain necessary antitrust or regulatory approvals could result in the deal lapsing and the payment of the £27 million break fee.
- Financing Risk: If the bridge facility is not repaid by maturity, it may convert to terms significantly less favorable to Platform. Commitment Parties may require Platform to issue notes to repay the facility.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the combined business, which involve risks and uncertainties that could cause actual results to differ materially.
Investor Verification Checklist
- Verify the final exchange rate used for the cash consideration if the deal closes after July 10, 2015.
- Confirm the status of antitrust clearances in relevant jurisdictions, particularly the U.S. and U.K.
- Monitor the proportion of Alent shareholders electing the share alternative versus cash to determine the final dilution impact on Platform.
- Review the terms of the permanent financing expected to replace the $1.875 billion interim facility.
- Assess the specific cost savings and synergy figures detailed in the Quantified Financial Benefits Statement (Exhibits 99.1 and 99.2).